FDA Approves Recurrence Indication for Pfizer Kidney Cancer Drug

The FDA added adjuvant therapy to prevent recurrence to the indications for Pfizer’s kidney cancer drug Sutent (sunitinib malate).

The indication is for adults with a high risk of recurrence of their cancer after surgical removal of a diseased kidney.

Sutent was initially approved in 2006 for treatment of kidney and stomach cancer.  It was approved for pancreatic cancer treatment in 2011.